Pediatric nonalcoholic fatty liver disease: Overview with emphasis on histology

Pediatric Nonalcoholic Fatty Liver Disease

Nonalcoholic Fatty Liver Disease Treatment

Nonalcoholic fatty liver disease (NAFLD) is increasing in pediatric age group parallel to the growing prevalence of obesity and overweight all around the world. So changing in life style and   interventions on obesogenic environment is cornerstone of NAFLD therapy in obese children. Some experts recommend that children and adolescents be encouraged to follow a low-fat, low-glycemic-index diet t...

Pediatric nonalcoholic fatty liver disease in 2009.

W ithin the so-called ‘‘globesity’’ epidemic, the International Obesity Task Force estimated that there at least 155 million persons are overweight/obese, including 30 to 45 million obese children worldwide. In parallel with epidemic obesity, nonalcoholic fatty liver disease (NAFLD) has also been increasingly recognized worldwide in the last decade. At present, NAFLD is identified as an importa...

Role of Docosahexaenoic Acid Treatment in Improving Liver Histology in Pediatric Nonalcoholic Fatty Liver Disease

INTRODUCTION Nonalcoholic fatty liver disease (NAFLD) is one of the most important causes of liver-related morbidity and mortality in children. Recently, we have reported the effects of docosahexaenoic acid (DHA), the major dietary long-chain polyunsaturated fatty acids, in children with NAFLD. DHA exerts a potent anti-inflammatory activity through the G protein-coupled receptor (GPR)120. Our a...

On the origin of pediatric nonalcoholic Fatty liver disease.

A t the time of diagnosis, the typical patient seen by a pediatric gastroenterologist for nonalcoholic fatty liver disease (NAFLD) is 12 years old. One of the most common questions that parents ask is: ‘‘when did this begin?’’ Rarely is there a clear answer; however, there is increasing evidence that NAFLD could begin at birth or even in utero. In this issue of the Journal of Pediatric Gastroen...